ArticleThorax2018
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.
Article in Thorax, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 170 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Contribution of Infectious Pathogens to Acute Respiratory Illness in Adults and Elderly
Drivers of Eosinophilic COPD Exacerbations
Who cites it
170 citing papers in PubMed, 5 syntheses or guidelines pooled it, 286 citations in OpenAlex.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Profiling of human lung and gut microbiomes in different conditions of chronic obstructive pulmonary disease using ontology-based evidence synthesis and reasoning.Frontiers in cellular and infection microbiology · 2026Pooled it
- Global research trends and thematic evolution of respiratory microbiota in COPD: a bibliometric study.Frontiers in medicine · 2026Pooled it
- The safety and efficacy of non-typeable Haemophilus influenzae and Moraxella catarrhalis vaccine in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Microbiota Emergencies in the Diagnosis of Lung Diseases: A Meta-Analysis.Frontiers in cellular and infection microbiology · 2021Pooled it
- Immunogenicity and safety of the non-typableHuman vaccines & immunotherapeutics · 2023Trial
- Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.Respiratory research · 2022Trial
- Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.International journal of chronic obstructive pulmonary disease · 2021Trial
- Review
- Review
- Characteristics of Respiratory Microbiome in COPD-A Literature Review.Advances in respiratory medicine · 2026Review
- Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026Review
- Beyond spirometry: understanding COPD origins to support a new diagnostic approach.ERJ open research · 2026Review
- Longitudinal change of lung microbiome in chronic obstructive pulmonary disease: a prospective cohort study.Respiratory research · 2026Article
- Inflammatory phenotype drives different immunosuppressive response in COPD exacerbations.BMC pulmonary medicine · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Pathogenesis of various pulmonary diseases by tuning immune response: insight from host-microbial crosstalk.Current research in microbial sciences · 2026Review
- Construction and Validation of a Machine Learning Model Based on Clinical and Microbiomic Features for Predicting High Mucus Secretion in COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Induced Sputum Microbial Diversity and Function Changes in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease by Metagenomic Sequencing: A Cross-Sectional Study.International journal of chronic obstructive pulmonary disease · 2026Article
- May nutrients and dietary supplements influence the gut-lung microbiota axis in chronic obstructive pulmonary disease and exacerbations?Archives of medical science : AMS · 2026Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlterations in the composition of the lung microbiome associated with adverse clinical outcomes, known as dysbiosis, have been implicated with disease severity and exacerbations in COPD.
objectiveTo characterise longitudinal changes in the lung microbiome in the AERIS study (Acute Exacerbation and Respiratory InfectionS in COPD) and their relationship with associated COPD outcomes.
methodsWe surveyed 584 sputum samples from 101 patients with COPD to analyse the lung microbiome at both stable and exacerbation time points over 1 year using high-throughput sequencing of the 16S ribosomal RNA gene. We incorporated additional lung microbiology, blood markers and in-depth clinical assessments to classify COPD phenotypes.
resultsThe stability of the lung microbiome over time was more likely to be decreased in exacerbations and within individuals with higher exacerbation frequencies. Analysis of exacerbation phenotypes using a Markov chain model revealed that bacterial and eosinophilic exacerbations were more likely to be repeated in subsequent exacerbations within a subject, whereas viral exacerbations were not more likely to be repeated. We also confirmed the association of bacterial genera, including
conclusionsSubtypes of COPD have distinct bacterial compositions and stabilities over time. Some exacerbation subtypes have non-random probabilities of repeating those subtypes in the future. This study provides insights pertaining to the identification of bacterial targets in the lung and biomarkers to classify COPD subtypes and to determine appropriate treatments for the patient. TRIAL REGISTRATION NUMBER: Results, NCT01360398.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.